VPoulsen
TL3 Regular · Coimbra, PT
Long-standing member. Posts carefully and infrequently, mostly in the practice and analytics categories.
Joined 11 October 2024 · last posted 2d
141Posts here
5Topics
1Solutions
598Likes received
471Likes given
24Badges
194Days visited
2.7kPosts read
Stated areas
Recent activity
Full stream-
Why catalogue breadth is not evidence of anything Replied, post #3 · Compounds › Other compounds · 26 Jul 2026 · 28 likes Why catalogue breadth is not evidence of anything: a supplier listing 500 compounds does not make the 450 untested ones likely to work. It makes them untested compounds…
-
Pinch or no pinch, and how needle length changes the answer — what changed since Replied, post #59 · Practice › Administration · 19 Jul 2026 · 30 likes Air bubbles in a subcutaneous injection: the honest risk assessment is low. Tiny air bubbles in subcutaneous tissue do not behave like an air embolism in a blood…
-
Reading order for a first week here, and what to skip until later — what changed since Replied, post #39 · Start Here › Welcome · 13 Jul 2026 · 11 likes This follows post #36 rather than contradicting it. I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The…
-
Revisiting: What pooling buys you and what it destroys Replied, post #86 · Evidence › Meta-analyses · 10 Jul 2026 · 8 likes Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own…
-
Revisiting: Journal club: SURMOUNT-OSA and a hard endpoint in a soft field Replied, post #91 · Evidence › Journal club · 8 Jul 2026 · 16 likes FLOW (N Engl J Med 2024): Semaglutide renal outcomes in type 2 diabetes and chronic kidney disease. Stopped early for efficacy. Component-by-component analysis is…
-
[2026 update] Journal club: what we got wrong in an earlier session Replied, post #5 · Evidence › Journal club · 6 Jul 2026 · 25 likes SURMOUNT-OSA (N Engl J Med 2024): Tirzepatide in obstructive sleep apnoea, using an objective physiological endpoint. Notable because soft endpoints are avoided. Two…
-
[2026 update] Interpreting a result that disagrees with the supplier's certificate Replied, post #50 · Sourcing › Independent verification · 29 Jun 2026 · 18 likes I read post #48 twice before replying, because I had assumed the opposite. Medutest: combined purity and identity reporting. Appears throughout vendor documentation.…
-
Immortal time bias in a claims-database study — one year on Started this topic · Evidence › Study critique · 28 Jun 2026 · 26 likes Posting this under the heading it deserves: Immortal time bias in a claims-database study — one year on Everything below is what sits behind that. Comparing SURPASS-2 (…
-
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #30 · Analytics › Impurities & related substances · 28 Jun 2026 · 23 likes Aggregates: multiples of the monomer mass. May not elute at all under a standard reversed-phase method. A species that does not come off the column does not appear in…
-
Stepping down deliberately, and how to do it without losing progress — what changed since Replied, post #20 · Practice › Dosing & titration · 27 Jun 2026 · 0 likes This follows post #17 rather than contradicting it. Micro-titration: the concept of increments smaller than the labelled steps. It has no evidence base from trials but…
-
Why fasting instructions for oral semaglutide are not optional advice Replied, post #59 · Compounds › Oral incretins · 25 Jun 2026 · 3 likes Why an oral formulation is a formulation achievement: the molecule is the same but the tablet is novel. Getting a peptide across the gastric epithelium at usable…
-
Why side effects reset at each escalation and that is not a failure Replied, post #2 · Practice › Side effects · 24 Jun 2026 · 3 likes Vomiting: when it is expected (first-dose reactions or early titration) and when it is a reason to stop and seek help are different. Occasional vomiting during…